Jessica Shull - Vicore Pharma Head Therapeutics

VICO Stock

SEK 7.84 0.36 4.39%

Insider

Jessica Shull is Head Therapeutics of Vicore Pharma Holding

Phone	46 3 17 88 05 60
Web	https://www.vicorepharma.com

Vicore Pharma Management Efficiency

The company has return on total asset (ROA) of (0.4902) % which means that it has lost $0.4902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9886) %, meaning that it generated substantial loss on money invested by shareholders. Vicore Pharma's management efficiency ratios could be used to measure how well Vicore Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Vicore Pharma to Peers

Predict price of Vicore Pharma

Vicore Pharma Holding has accumulated 320 K in total debt. Vicore Pharma Holding has a current ratio of 19.43, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Vicore Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Vicore Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vicore Pharma Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vicore to invest in growth at high rates of return. When we think about Vicore Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Peter Nygren	Oncopeptides AB	64
	Kristina Luthman	Oncopeptides AB	N/A
	Pr MD	Oncopeptides AB	N/A
	Annika MBA	Oncopeptides AB	57
	Anne Lanner	Hansa Biopharma AB	54
	MBA MSc	Saniona AB	63
	Rami Levin	Saniona AB	54
	Anita BCom	Saniona AB	55
	Linda Holmstrom	Oncopeptides AB	N/A
	Klaus Sindahl	Hansa Biopharma AB	N/A
	Jorgen Drejer	Saniona AB	68
	Janus Larsen	Saniona AB	51
	Emanuel Bjrne	Hansa Biopharma AB	50
	Karin Nielsen	Saniona AB	N/A
	Jakob Lic	Oncopeptides AB	51
	Palle MS	Saniona AB	65
	MSc MD	Oncopeptides AB	N/A
	Katja Margell	Hansa Biopharma AB	N/A
	MSc MSc	Oncopeptides AB	53
	Sren MSc	Hansa Biopharma AB	58

Vicore Pharma Holding AB , through its subsidiaries, operates as a biotech company. Vicore Pharma Holding AB was founded in 2000 and is based in Mlndal, Sweden. Vicore Pharma is traded on Stockholm Stock Exchange in Sweden. Vicore Pharma Holding (VICO) is traded on Stockholm Exchange in Sweden and employs 23 people.

Management Performance

	Return On Equity	-0.99
	Return On Asset	-0.49

Vicore Pharma Holding Leadership Team

Elected by the shareholders, the Vicore Pharma's board of directors comprises two types of representatives: Vicore Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vicore. The board's role is to monitor Vicore Pharma's management team and ensure that shareholders' interests are well served. Vicore Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vicore Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Kicki Johansson, Chief Officer
	Johan Raud, Chief Officer
	Elin Rosendahl, VP Devel
	Nina Carlen, Chief Officer
	Asa Magnusson, Chief Officer
	Rohit Batta, Chief Officer
	Hans Jeppsson, Chief Officer
	CarlJohan MD, Chief Officer
	Jessica Shull, Head Therapeutics
	Johanna Grans, Head Devel

Vicore Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vicore Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.99
	Return On Asset	-0.49
	Current Valuation	1.22 B
	Shares Outstanding	81.85 M
	Shares Owned By Insiders	16.14 %
	Shares Owned By Institutions	51.89 %
	Price To Earning	163.82 X
	Price To Book	8.67 X
	EBITDA	(293.13 M)
	Net Income	(296.48 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vicore Stock Analysis

When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC